Checkpoint Therapeutics Inc expected to post a loss of 78 cents a share - Earnings Preview

Checkpoint Therapeutics

08/08/2023 16:11

* Checkpoint Therapeutics Inc  CKPT.OQ   CKPT.O  is expected
to show a fall in quarterly revenue when it reports  results on
August 10 (estimated). 
    * The Waltham Massachusetts-based  company is expected to
report 
a 72.2% decrease in revenue to $5 thousand from $18 thousand a
year ago, according to the mean estimate from 4 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Checkpoint
Therapeutics
Inc is for a loss of 78 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Checkpoint
Therapeutics Inc is $19​, above​ its last closing price
of $2.23. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -1.09       -1.07      -0.89     Beat    16.6
 Dec. 31 2023  -1.30       -1.31      -2.29     Missed  -75.3
 Sep. 30 2022  -1.47       -1.47      -1.20     Beat    18.2​
 Jun. 30 2022  -1.78       -1.72      -1.60     Beat    7.2
 ​​Mar.        -1.39       -1.42      -2.00     Missed  -40.8
 31 2022                                                
 Dec. 31 2021  -1.50       -1.54      -3.90     Missed  -153.2
                                                        ​
 Sep. 30 2021  -1.34       -1.36      -1.40     Missed  -2.9
 Jun. 30 2021  -1.01       -1.04      -1.20     Missed  -15.4
 This summary was machine generated August 8 at 15:11 GMT.  All
figures in US dollars  unless otherwise stated